ArticlePathology oncology research : POR2020

Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma.

Lajos Géczi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.